Latest From Affymax Inc.
US Inhaled CNS drug biotech Alexza looks set to be acquired by Spain’s Ferrer, the licensee of its only marketed product Adasuve outside of the US, in an all-cash offer that includes contingent value rights.
CMS should not limit proposed transitional payments for IV and injectable ESRD drugs based on the current criteria for bundling, Amgen says. Company's approach could benefit its new IV caclimimetic drug candidate.
In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.
A recent influx of cash to the small biotech will allow Syndax to develop its oncology asset on its own, beginning with a Phase III trial and potentially continuing to U.S. commercialization.
- Drug Discovery Tools
- Large Molecule
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Renal System
- Affymax Research Institute
- North America
- Parent & Subsidiaries
- Affymax Inc.
- Senior Management
Jonathan M Couchman, Pres. & CEO
Mark Thompson, CFO
- Contact Info
Phone: (650) 812-8700
4001 Miranda Ave.
Palo Alto, CA 94304
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.